CUE
Price
$1.71
Change
-$0.03 (-1.72%)
Updated
May 17, 6:59 PM EST
106 days until earnings call
DNLI
Price
$20.51
Change
+$0.27 (+1.33%)
Updated
May 17, 6:59 PM EST
79 days until earnings call
Ad is loading...

CUE vs DNLI

Header iconCUE vs DNLI Comparison
Open Charts CUE vs DNLIBanner chart's image
Cue Biopharma
Price$1.71
Change-$0.03 (-1.72%)
Volume$71.83K
CapitalizationN/A
Denali Therapeutics
Price$20.51
Change+$0.27 (+1.33%)
Volume$477.13K
CapitalizationN/A
View a ticker or compare two or three
CUE vs DNLI Comparison Chart

Loading...

CUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CUE vs. DNLI commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a StrongSell and DNLI is a Hold.

COMPARISON
Comparison
May 19, 2024
Stock price -- (CUE: $1.71 vs. DNLI: $20.51)
Brand notoriety: CUE and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CUE: 39% vs. DNLI: 67%
Market capitalization -- CUE: $83.18M vs. DNLI: $2.92B
CUE [@Biotechnology] is valued at $83.18M. DNLI’s [@Biotechnology] market capitalization is $2.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $586.12B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CUE’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CUE’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CUE is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CUE’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CUE’s TA Score: 3 bullish, 7 bearish.
  • DNLI’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than CUE.

Price Growth

CUE (@Biotechnology) experienced а -1.72% price change this week, while DNLI (@Biotechnology) price change was +12.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

CUE is expected to report earnings on Sep 02, 2024.

DNLI is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CUE with price predictions.
OPEN
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DNLI($2.93B) has a higher market cap than CUE($83.2M). DNLI YTD gains are higher at: -4.427 vs. CUE (-35.227).
CUEDNLICUE / DNLI
Capitalization83.2M2.93B3%
EBITDAN/AN/A-
Gain YTD-35.227-4.427796%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CUE vs DNLI: Fundamental Ratings
CUE
DNLI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9890
PRICE GROWTH RATING
1..100
6446
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CUE's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for DNLI (79). This means that CUE’s stock grew somewhat faster than DNLI’s over the last 12 months.

CUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that CUE’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as CUE (98). This means that DNLI’s stock grew similarly to CUE’s over the last 12 months.

DNLI's Price Growth Rating (46) in the Biotechnology industry is in the same range as CUE (64). This means that DNLI’s stock grew similarly to CUE’s over the last 12 months.

DNLI's P/E Growth Rating (97) in the Biotechnology industry is in the same range as CUE (100). This means that DNLI’s stock grew similarly to CUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CUEDNLI
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
CUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BBBXF0.100.01
+10.71%
Brixton Metals Corp.
JMPLY46.930.36
+0.78%
Johnson Matthey plc
SVNDY12.95-0.01
-0.08%
Seven & I Holdings Co., Ltd.
BOUYY7.68-0.05
-0.65%
Bouygues SA
PET1.93-0.10
-4.93%
Wag! Group Co

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with DNLI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-1.72%
DNLI - CUE
39%
Loosely correlated
+1.33%
PRME - CUE
38%
Loosely correlated
+0.57%
PSTX - CUE
38%
Loosely correlated
-4.63%
XNCR - CUE
38%
Loosely correlated
+2.54%
ZYME - CUE
37%
Loosely correlated
-2.77%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with BEAM. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.33%
BEAM - DNLI
68%
Closely correlated
+3.49%
NTLA - DNLI
63%
Loosely correlated
+0.19%
JANX - DNLI
59%
Loosely correlated
-0.86%
LGND - DNLI
51%
Loosely correlated
+1.22%
VCYT - DNLI
50%
Loosely correlated
-2.22%
More